Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 8;14(8):1648.
doi: 10.3390/pharmaceutics14081648.

-Omic Approaches and Treatment Response in Rheumatoid Arthritis

Adela Madrid-Paredes  1   2 , Javier Martín  2 , Ana Márquez  2
Affiliations
Review

-Omic Approaches and Treatment Response in Rheumatoid Arthritis

Adela Madrid-Paredes et al. Pharmaceutics. .

Abstract

Rheumatoid arthritis (RA) is an inflammatory disorder characterized by an aberrant activation of innate and adaptive immune cells. There are different drugs used for the management of RA, including disease-modifying antirheumatic drugs (DMARDs). However, a significant percentage of RA patients do not initially respond to DMARDs. This interindividual variation in drug response is caused by a combination of environmental, genetic and epigenetic factors. In this sense, recent -omic studies have evidenced different molecular signatures involved in this lack of response. The aim of this review is to provide an updated overview of the potential role of -omic approaches, specifically genomics, epigenomics, transcriptomics, and proteomics, to identify molecular biomarkers to predict the clinical efficacy of therapies currently used in this disorder. Despite the great effort carried out in recent years, to date, there are still no validated biomarkers of response to the drugs currently used in RA. -Omic studies have evidenced significant differences in the molecular profiles associated with treatment response for the different drugs used in RA as well as for different cell types. Therefore, global and cell type-specific -omic studies analyzing response to the complete therapeutical arsenal used in RA, including less studied therapies, such as sarilumab and JAK inhibitors, are greatly needed.

Keywords: DNA methylation; epigenomics; genomics; microRNAs; proteomics; rheumatoid arthritis; transcriptomics; treatment response.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
-Omic approaches for a personalized therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Karami J., Masoumi M., Khorramdelazad H., Bashiri H., Darvishi P., Sereshki H.A., Shekarabi M., Sahebkar A. Role of Autophagy in the Pathogenesis of Rheumatoid Arthritis: Latest Evidence and Therapeutic Approaches. Life Sci. 2020;254:117734. doi: 10.1016/j.lfs.2020.117734. - DOI - PubMed
    1. Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid Arthritis. Lancet. 2016;388:2023–2038. doi: 10.1016/S0140-6736(16)30173-8. - DOI - PubMed
    1. Edilova M.I., Akram A., Abdul-Sater A.A. Innate Immunity Drives Pathogenesis of Rheumatoid Arthritis. Biomed. J. 2021;44:172–182. doi: 10.1016/j.bj.2020.06.010. - DOI - PMC - PubMed
    1. Smolen J.S., Landewé R.B.M., Bijlsma J.W.J., Burmester G.R., Dougados M., Kerschbaumer A., McInnes I.B., Sepriano A., Van Vollenhoven R.F., De Wit M., et al. EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2019 Update. Ann. Rheum. Dis. 2020;79:S685–S699. doi: 10.1136/annrheumdis-2019-216655. - DOI - PubMed
    1. Callaghan C.A., Boyter A.C., Mullen A.B., McRorie E.R. Biological Therapy for Rheumatoid Arthritis: Is Personalised Medicine Possible? Eur. J. Hosp. Pharm. Sci. Pract. 2014;21:229–237. doi: 10.1136/ejhpharm-2013-000386. - DOI